Viking Therapeutics, Inc. (VKTX) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Viking Therapeutics, Inc. (VKTX) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Seeking Alpha • 20 hours ago

Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider

The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $29.78, representing a +1.53% change from its previous close.

Zacks Investment Research • 17 hours ago

Bull vs. Bear: The Quick Take on Viking Therapeutics Stock

Eli Lilly and Novo Nordisk are much larger companies and already have oral weight loss pills on the market. Investors are hoping Viking's VK2735 will prove efficacious and safe in its Phase 3 clinical trials.

The Motley Fool • Jun 3, 2026

1 Sector Warren Buffett and Greg Abel Are Largely Ignoring -- and Why Investors Shouldn't

Buffett, as CEO of Berkshire Hathaway, delivered six decades of market-beating returns. Abel took over the CEO role in January and aims to follow the path traced by the investing giant.

The Motley Fool • Jun 3, 2026

Viking Therapeutics' Q3 Catalyst That Could Turn Eli Lilly's and Novo Nordisk's Daily Weight Loss Pill Strategy Upside Down

VK2735 is being developed in both subcutaneous and oral forms, and upcoming Phase 1 maintenance trial results are a major catalyst. VK2735 may offer efficacy advantages over competitors' oral drugs.

The Motley Fool • Jun 2, 2026

Why Is Viking Therapeutics (VKTX) Up 3.2% Since Last Earnings Report?

Viking Therapeutics (VKTX) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • May 29, 2026

If Viking Therapeutics Is Acquired, Here's Who Wins

Viking Therapeutics (VKTX) is the most closely watched biotech acquisition target. A buyer such as Eli Lilly (LLY) would benefit, as would Viking shareholders, and at least one GLP-1 competitor.

24/7 Wall Street • May 26, 2026

Prediction: These 2 Obesity Drug Stocks Could Double in 2026

The weight loss opportunity is a significant one for companies and investors -- and companies involved have seen their shares soar. Analysts predict the market will reach almost $100 billion within a few years.

The Motley Fool • May 26, 2026

Don't Buy Viking Therapeutics Stock Until You Read This

Enthusiasm for Viking Therapeutics and its weight-loss candidate has come and gone, and for good reason. While Viking is still trying to bring its first candidate to market, rivals are already increasing the competition with new product launches.

The Motley Fool • May 26, 2026

Is Viking Therapeutics a Top Takeover Target?

Big pharma still needs additional late-stage obesity drug assets. Viking's obesity pipeline could attract major pharmaceutical acquisition interest.

The Motley Fool • May 23, 2026